34 Comments
 
Controversial

Large Boutiques: PWP, CVP (esp Biotech/Pharma), EVR

BBs: GS, JPM, MS

MM: Cowen, SVB, HW, WB

 

Jefferies piper for sure as well with all mentioned previously. Would also add jmp after being acquired by citizens and potentially RJ

 
Most Helpful

this one comes back every so often. 

this for example:

https://www.wallstreetoasis.com/forum/investment-banking/best-healthcar…

it's hard because not everyone does everything and excels at it.

are you looking at fees? fees per banker? number of deals? specific verticals? specific types of deals (ECM or M&A? sponsor or corporates)...

a few things that stand out:

- JPMorgan probably consistently across all market segments. lots of bodies on the ground. covers all verticals

- some MM firms have very specific angles. Piper dominates in med tech for example. also fees share of Piper, SVB, Cowen for biotech IPO is impressive. for M&A less so (Piper was doing well on spec pharma M&A but their top banker left for Barclays (which is incidentally strong on spec pharma).

sell-side biotech? centerview #1 by far; Lazard fighting for share too. JPmorgan growing presence.

Large cap pharma advisory? most EBs (albeit don't print with every large pharma - exceptions are probably Evercore and Centerview); then JP / MS / GS / BAML (no specific order). Citi somewhat behind; others are more aligned with specific corporates.

CDMO? beyond thre BBs, RBC had a strong market share, but top CDMO banker left for Truist. 

HL is focused on buy & build, also good presence in healthcare marketing companies. some good presence in medtech too (notably Europe, although team is recent)

Jefferies is strong across verticals, quite MM focused, M&A is PE focused as well

 

I think SVBs M&A fees last year were pretty sizeable. About 50%+ of their revenue was from m&a

 

Services kills it volume-wise, pharma still holds a lot of big relationships but low activity from them (besides equity stuff), and unsure what the deal is with medtech after the junior turnover / culture problems. Definitely solid as a whole platform

 

HL, Jeffries, Moelis. for all things services / retail / multi site. You’ll see some BBs win mandates in this vertical obviously but not at the same velocity. I’d say HL wins the most but will average smaller deal size wise.

I don’t know a ton about the other verticals but I know Baird has a pretty solid pharma services platform out in Charlotte.

SVB and Tripletree also have great groups but I’d say are a slight cut below the rest.

 

Rem animi non voluptatem cumque enim. Repellat voluptatem est commodi eaque. Corporis porro harum eos quas ad.

Reiciendis ratione expedita quis quia dicta quidem. Recusandae et ut et. Aut repudiandae debitis dignissimos vel error sunt vitae. Qui iste culpa sed consequuntur.

 

At aut rem explicabo quisquam expedita. Nesciunt beatae qui est deleniti. Quia omnis hic dolorem impedit optio id labore. Voluptas aliquam itaque perspiciatis blanditiis. Enim assumenda optio commodi qui exercitationem culpa ducimus. Maxime alias blanditiis cumque aspernatur cumque hic. Voluptatem et omnis accusantium veniam facilis veniam reprehenderit.

Quod sed quia voluptatibus dolorem corrupti enim inventore. Aut voluptatibus ex quasi nostrum excepturi explicabo.

Deserunt beatae excepturi odio unde. Repudiandae provident debitis quo assumenda tempora enim voluptatem. Ut quas ea cupiditate ab.

[Comment removed by mod team]

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.1%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.8%
  • Morgan Stanley 01 98.3%
  • BMO Capital Markets 13 97.7%
  • Banco Santander 01 97.1%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.1%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (15) $434
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (13) $156
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
DrApeman's picture
DrApeman
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
GameTheory's picture
GameTheory
98.9
9
Betsy Massar's picture
Betsy Massar
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”